UnknownPhase 4

Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer

France58 participantsStarted 2005-10

Plain-language summary

RATIONALE: Learning about the relationship between platinum levels in the blood and neurotoxicity in patients receiving oxaliplatin may help plan treatment and may help patients live more comfortably. PURPOSE: This phase IV trial is studying the relationship between platinum levels in the blood and neurotoxicity in patients who are receiving oxaliplatin for gastrointestinal cancer.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Diagnosis of gastrointestinal cancer * Receiving or planning to receive 8 months of oxaliplatin-based chemotherapy * No pre-existing neuropathy * No CNS disease or cerebral metastases PATIENT CHARACTERISTICS: * WHO 0-1 * Life expectancy ≥ 12 weeks * No biliary or gastro-duodenal obstruction * No familial, social, geographical, or psychological condition that would preclude study treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No other concurrent drug or agent that is potentially neurotoxic

What they're measuring

Relationship between residual platinum levels in the blood and persistent neurotoxicity

Trial details

NCT IDNCT00274885

SponsorGERCOR - Multidisciplinary Oncology Cooperative Group

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Cancer trials